Emergex Vaccines is a biotechnology company focused on developing a broad range of synthetic T cell-priming vaccines and immunotherapy candidates targeting infectious diseases and immunotherapy indications. Utilizing core proprietary technologies, the company aims to elicit broad and long-lasting cellular immune responses to address significant global health threats. Their pipeline includes candidates for Betacoronavirus, Dengue Fever, Universal Influenza, and intracellular bacterial infectious diseases. Emergex's vision is to positively impact global human health through innovative T cell-priming products.